Ultime notizie per Raytech Holding (NASDAQ:RAY) Azioni

Raytech Holding Ltd is principally engaged in product designing and manufacturing of various product ranges such as Hair Care, Men's Care and Women's Care products. It has sourced and wholesaled a wide range of personal care electrical appliances, which can be broadly classified into seven categories: hair styling series, including hair dryer, hair straightener and curling iron; trimmer series, including facial shaver, nose trimmer and eyebrow trimmer; eyelash curler; neck care series; nail care series; tooling and other personal care appliances such as body and facial brush, reset brush, callus remover, sonic peeling, handy fan and others. Raytech manufactures products under OEM and ODM.

Raytech Holding

wall street chart shutter2

News

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

TDUP

Settore consumi: allerta su 2 titoli! Inversione di rotta in vista? Segnali chiave e implicazioni per il tuo portafoglio.

2 titoli del settore dei beni di consumo che potrebbero subire una correzione

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

$LTC

$RAY

$TRUMP

$TRX

$XCN

$XRP

Gennaio è stato un mese di importanti sviluppi nel settore delle criptovalute. È stata lanciata una meme coin direttamente collegata al presidente degli Stati Uniti, che ha fatto rapidamente parlare di sé in tutto il mondo, raggiungendo una capitalizzazione di miliardi di dollari.

Questa meme coin ha guadagnato il 1.400% a gennaio e non è TRUMP

Raytech Holding Limited - ordinary shares

Raytech Holding Ltd

Raydium - United States Dollar

Erayak Power Solution Group Inc. - Class A Ordinary Shares

Erayak Power Solution Group Inc

Rayliant Quantamental China Equity ETF

The Advisors' Inner Circle Fund III Rayliant Quantitative Developed Market Equity ETF

Rayliant Quantamental Emerging Market ex-China Equity ETF

The Advisors' Inner Circle Fund III Rayliant SMDAM Japan Equity ETF

Global X Solar ETF

Rayont Inc

HC Wainwright &amp; Co. analyst Robert Burns reiterates Immix Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMMX#NASDAQ">IMMX</a>) with a Buy and maintains $7 price target.

Price Target

Reiteration

Analyst Ratings

IMMX

HC Wainwright & Co. Reiterates Buy on Immix Biopharma, Maintains $7 Price Target

Vigil Neuroscience, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIGL#NASDAQ">VIGL</a>), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced an update on the Phase 2 IGNITE open-label clinical trial evaluating iluzanebart, a monoclonal antibody TREM2 agonist, for the potential treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP).
Iluzanebart demonstrated a favorable safety, tolerability and pharmacokinetic profile across both the 20 mg/kg and 40 mg/kg dose cohorts. The Phase 2 IGNITE trial showed no beneficial effects on biomarker or clinical efficacy endpoints with treatment of iluzanebart in ALSP patients. Based upon these results, the Phase 2 long-term extension study is being discontinued in accordance with the process previously disclosed.

VIGL

Vigil Neuroscience Discontinues Phase 2 Extension Study For Iluzanebart After Trial Results

HC Wainwright &amp; Co. analyst Emily Bodnar upgrades AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) from Neutral to Buy and raises the price target from $22 to $38.

Upgrades

ANAB

HC Wainwright & Co. Upgrades AnaptysBio to Buy, Raises Price Target to $38

- Further protection granted in key territory applying to the significant and growing aesthetic and reconstructive markets -
 &nbsp;

CLGN

CollPlant Secures European Patent For rhCollagen-Based Soft Tissue Fillers And Regenerative Implants

HC Wainwright &amp; Co. analyst Andres Maldonado reiterates ImmunityBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>) with a Buy and maintains $8 price target.

IBRX

HC Wainwright & Co. Reiterates Buy on ImmunityBio, Maintains $8 Price Target

The Aluminium Association of Canada (AAC) has condemned the U.S. government's move to impose a 50% tariff on Canadian <a target="_blank" href="https://www.benzinga.com/topic/aluminum" rel="noreferrer noopener">aluminum</a>, calling it a protectionist misfire that risks destabilizing North America's integrated manufacturing base and driving higher inflation across key sectors.
"A 50% tariff on Canadian aluminum will suppress demand across the continent — whether the metal is produced in Canada or the U.S.," Jean Simard, AAC's president and CEO, <a target="_blank" href="https://aluminium.ca/wp-content/uploads/2025/06/AAC_PRESS-RELEASE_US-Tariffs_50_June-3-2025_FINAL.pdf" rel="noreferrer noopener">said</a> in a press release.
"It will impact workers on both sides of the border and disrupt key sectors including defense, construction, and automotive," he stated.
The tariff, enacted last Wednesday following an executive order from President Donald Trump, effectively prices Canadian exports out of the U.S. market at $1,349.50 per metric ton. Simard warned that the move may force Canadian producers to reorient trade toward the European Union and away from their most critical industrial partner.
Food packaging is among the industries most exposed to these tariffs, as large companies such as Campbell Soup (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPB#NASDAQ">CPB</a>) and Coca-Cola (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>) heavily rely on aluminum for their products.
The domestic Can Manufacturers Institute (CMI) also responded to Trump's decision, pointing out how aluminum and tinplate steel tariffs would hurt American families.
"Doubling the steel tariff will further increase the cost of canned goods at the grocery store," CMI president Robert Budway <a target="_blank" href="https://www.cancentral.com/can-manufacturers-institute-opposes-president-trumps-doubling-of-steel-tariffs/" rel="noreferrer noopener">said</a> on May 30. "These metal tariffs put our nation's food security at risk."
Nine domestic mill production lines have closed since the original 2018 tariffs on tin mill steel, leaving only three operational facilities. Thus, the domestic industry relies on roughly 80% of tin mill steel imports and a significant portion of aluminum.
Canada annually ships 2.7 million metric tons of aluminum to the U.S., much of which is transformed into beverage cans, canned food containers, and consumer packaging.
That raw material supports over 700,000 American manufacturing jobs, while Canada's aluminum sector directly employs 9,500 workers. Combined, the binational aluminum value chain contributes more than $228 billion annually to the U.S. economy.
Thanks to its abundant hydropower, Canada produces low-carbon aluminum at a cost and emissions profile that is far below that of many of its global competitors. That energy benefit is enormous — equivalent to 40 million megawatt-hours per year, or the annual output of four Hoover Dams.
Simrad noted that the Canadian industry supports the U.S. goal of increasing domestic aluminum production capacity from 50% to 80% of national demand, but added that tariffs undermine the investment certainty needed to build that capacity.
"Even if U.S. output doubles, it will still be a net importer," he said.
Instead, the AAC and CMI urge the U.S. to target the real threat: subsidized overcapacity from China. Canada already leads the world in aluminum traceability and anti-dumping enforcement. "Canadian aluminum is not — and will not be — a backdoor for unfair trade," Simard stated. "Undermining a trusted partner only weakens the foundation we both stand on."
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/commodities/25/06/45746216/third-delay-in-mali-court-battle-over-barricks-gold-complex" target="_blank" rel="noreferrer noopener">Third Delay In Mali Court Battle Over Barrick's Gold Complex</a></li>
</ul>
Photo via Shutterstock

Government

Commodities

Politics

ABEV

Coca-Cola European Partners plc Ordinary Shares

CCEP

Fomento Economico Mexicano S.A.B. De C.V.

HEINY

MNST

US Aluminum Tariffs Risk Supply Chain And Food Security, Industry Insiders Warn

Trucordia Announced It Will Receive A $1.3B Strategic Investment From Global Investment Firm Carlyle's Global Credit Platform

<a href="https://api.newsfilecorp.com/redirect/QOevbfBjjk">BioHarvest Sciences Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHST#NASDAQ">BHST</a>) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced the launch of VINIA&#xAE; DailyChews 2X Formula, a first-of-its-kind chew designed to increase nitric oxide production and arterial dilation, and to enhance blood flow and oxygen delivery for athletes and individuals with highly active lifestyles. VINIA&#xAE; DailyChews 2X Formula are now available for purchase in a 30-count pack on <a href="https://api.newsfilecorp.com/redirect/m3rNmcmvz7">VINIA.com</a>.
Formulated with a double dose of BioHarvest's proprietary red grape cell composition, VINIA&#xAE; DailyChews 2X Formula are officially Informed Sport-certified, underscoring the Company's commitment to cleaner, safer, and effective performance nutrition. The globally recognized certification ensures every batch is tested for banned substances, making it a trusted choice for professional athletes, military personnel, and fitness enthusiasts alike.
Each individually packaged VINIA&#xAE; DailyChews 2X Formula contains 800mg of VINIA&#xAE; and 12 mg of Piceid resveratrol, which has been clinically shown to increase arterial dilation. This arterial dilation improves blood flow, delivering more oxygen and nutrients to the body's muscles, tissues, and cells, improving physical energy and mental alertness.

BHST

BioHarvest Sciences Launches VINIA DailyChews 2X Formula, For Athletes And Individuals With Highly Active Lifestyles

American Express Canada, The Official Payments Partner Of Formula 1 Is Launching Maison Amex, A Bespoke Pit Stop For Select Cardmembers During The Formula 1 Pirelli Grand Prix Du Canada 2025 Race Weekend

Today, CIBC announced the launch of a new dedicated <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4441780-1&amp;h=1050257808&amp;u=https%3A%2F%2Fcibc.com%2Fbusinessskilledtrades&amp;a=Business+Banking+program">Business Banking program</a>&nbsp;tailored for skilled trades professionals. This initiative builds on the success of CIBC's first-of-its-kind skilled trades <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4441780-1&amp;h=571380162&amp;u=https%3A%2F%2Fwww.cibc.com%2Fen%2Fpersonal-banking%2Fbank-accounts%2Fskilled-trades.html&amp;a=Personal+Banking+program">Personal Banking program</a> introduced last June. Together, these initiatives are designed to enhance support for a sector that is crucial to the Canadian economy.

CIBC Launches Business Banking Program to Support Skilled Trades Pros Across Canada

MAIN

Main Street Capital Announced That It Recently Completed A New Portfolio Investment To Facilitate The Minority Recapitalization Of A Leading Aerial Survey Platform, With Main Street Funding $45.4M In A Combination Of First Lien, Senior Secured Term Debt And A Direct Equity Investment

GUTS

Fractyl, Bariendo Ink LOI To Develop Scalable Clinical Pathway For Revita In Metabolic Endoscopy Centers Nationwide

SION-719 and SION-451 were generally well tolerated and achieved desired pharmacokinetic targets that reinforce their potential as either an add-on to standard of care or in a Sionna dual combination
Sionna plans to advance SION-719 to a Phase 2a proof-of-concept add-on to standard of care trial in cystic fibrosis patients, and SION-451 to a Phase 1 healthy volunteer dual combination trial
Next trials to initiate in the second half of 2025 with topline data expected in mid-2026
Sionna to hold a conference call today at 8:00 a.m. ET
WALTHAM, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SION#NASDAQ">SION</a>), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced positive data from its Phase 1 clinical trials of SION-719 and SION-451, the company's first-in-class nucleotide-binding domain 1 (NBD1) stabilizers, in healthy volunteers. Both NBD1 stabilizers were generally well tolerated and achieved pharmacokinetic (PK) concentration targets established using Sionna's preclinical CF human bronchial epithelial (CFHBE) model. These data reinforce the potential of both NBD1 stabilizers to provide clinically meaningful benefit for CF patients, including the potential for wild-type CFTR function, either as an add-on to standard of care (SOC), or in a proprietary dual combination with complementary modulators. Sionna plans to advance both NBD1 stabilizers to the next stage of clinical development — SION-719 to a Phase 2a proof-of-concept (POC) trial in CF patients as an add-on to SOC, and SION-451 to a Phase 1 proprietary dual combination trial in healthy volunteers.

SION

Sionna Therapeutics Reports Data From Phase 1 Clinical Trials Of SION-719 And SION-451, First-In-Class NBD1 Stabilizers, In Healthy Volunteers

New Era Helium, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEHC#NASDAQ">NEHC</a>) ("NEHC" or the "Company"), a next-gen exploration and production platform in the Permian Basin, today announced that the Texas Critical Data Centers, LLC ("TCDC") joint venture has entered into a non-binding Memorandum of Understanding ("MOU") with PowerForward Energy Solutions ("PFES") to provide 250MW of on-site generation capacity to power its planned AI and high-performance computing ("HPC") campus in Ector County, Texas.
TCDC, the joint venture established between New Era Helium and Sharon AI, Inc. in 2024, is focused on building a 250MW data center to support the rapidly growing demand for AI and cloud GPU infrastructure. Under the terms of the MOU, signed on April 23, 2025, PFES has agreed to manufacture, install, and operate 250MW of generation assets at the TCDC site, with the first 100MW targeted for delivery within 12 months of funding and full deployment expected within 18 months.
PFES is a joint venture between Progen Industries, a U.S.-based manufacturer of natural gas-fired engine-driven generators, and MBS Engineering, Inc. The partners bring more than 70 years of combined experience in delivering resilient, distributed power solutions for critical infrastructure.
Work at the site continues to progress, including the completion of the Phase I Environmental Site Assessment and ongoing planning for air permitting. NEHC, Sharon AI, and PFES are also jointly evaluating carbon capture technologies. TCDC is in active discussions with potential customers, including parties interested in acquiring powered land for near-term deployment. Near-term milestones include securing natural gas supply agreements and advancing interconnection planning with regional grid partners.

NEHC

New Era Helium JV to Power Texas AI Data Center with 250MW from On-Site Generators

JBLU

JetBlue Announced The Official Launch Of Paisly, Llc, Formerly Jetblue Travel Products

<a href="https://www.veeva.com/">Veeva Systems</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) and Sarah Cannon Research Institute (SCRI) today announced a strategic collaboration to drive speed and efficiency in oncology clinical trials across SCRI's more than 200 research site locations. SCRI is adopting <a href="https://www.veeva.com/products/veeva-clinical-platform/">Veeva Clinical Platform</a> to unify its contract research organization (CRO) and site management organization (SMO) on a single platform for seamless data flow across clinical teams and research sites.

VEEV

Veeva Teams Up with Sarah Cannon to Speed Up Cancer Trials at 200+ Research Sites

Cohort 3 demonstrates earlier and deeper responses compared to cohorts 1-2
All three cohorts show separation from placebo with statistically significant difference from placebo at day 28
Cohort 3 demonstrates clinically meaningful reduction in itch as early as day 8
Enrollment initiated in extension cohort study exploring the same cohort 3 dose (200 mg BID) for a longer 8-week treatment period
SOUTH SAN FRANCISCO, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>), a clinical-stage biopharmaceutical company, today announced new interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis. The data includes 28-day follow up results for all patients in cohort 3 and continues to show earlier and deeper responses in cohort 3 (200 mg twice per day, total daily dose 400 mg) compared to cohorts 1 and 2 (100 mg twice per day and 200 mg once per day, total daily dose 200 mg). Overall, data from cohorts 1-3 of the trial have demonstrated a favorable safety and efficacy profile, including a statistically significant improvement in Eczema Area and Severity Index (EASI) score for the soquelitinib treated patients compared to placebo at day 28 (p=0.036).

CRVS

Corvus Pharma Announces New Interim Data From Randomized, Double-Blind, Placebo-Controlled Phase 1 Clinical Trial Evaluating Soquelitinib In Patients With Moderate To Severe Atopic Dermatitis

<a href="https://www.veeva.com/">Veeva Systems</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) today announced Astellas has chosen <a href="https://www.veeva.com/products/crm-suite/crm/">Veeva Vault CRM</a>&nbsp;globally and <a href="https://www.veeva.com/cn/veeva-china-crm-suite-en/">Veeva China CRM</a> for China.
&nbsp;
"At Astellas, we discover and deliver transformative therapies for patients around the world," said Nick Eshkenazi, chief digital and transformation officer at Astellas. "Having a foundation for commercial agility and execution is crucial. Our collaboration with Veeva will provide us with technology solutions and data to enhance our agility as a company while we partner with an entity that shares our values and focus on patients."
"Astellas is a leader in improving the health of people around the world through their innovative science and healthcare solutions," said Matt Farrell, president, commercial strategy at Veeva. "With Vault CRM, we are excited to deepen our partnership to support Astellas in that mission."
Vault CRM addresses the industry's unique and evolving country-specific business needs and compliance requirements. It is part of the Vault CRM Suite that connects sales, marketing, and medical teams for seamless collaboration and more effective commercial execution.

Astellas Picks Veeva's Vault CRM to Boost Global Sales and Marketing Agility

On June 4, 2025, New Century Logistics (BVI) Limited (hereinafter referred to as "New Century") has entered into a Letter of Intent (hereinafter referred to as "LOI") with Ms. Chiu Nga Ting, the sole shareholder of Asiatic Logistics Limited ( hereinafter referred to as "Asiatic"), to acquire 51% of the issued and outstanding shares of Asiatic. This strategic move is aimed at enhancing New Century's presence in Asia and advancing the development of a comprehensive global logistics ecosystem. The signing of the LOI signifies a significant milestone in the ongoing strategic partnership between New Century and Asiatic. It builds upon the existing framework agreement and underscores the mutual commitment to leveraging synergies and optimizing operational efficiencies. This acquisition is expected to bolster New Century's core advantages in the Asian market and catalyze the full-chain upgrade of its global logistics network.
Strategic upgrade: from framework cooperation to equity binding, build a deep collaborative ecology
New Century and Asiatic have a long-standing history of collaboration. In July 2023, the two parties entered into a Strategic Cooperation Framework Agreement, focusing on complementary transportation services, joint market expansion, and resource sharing. The goal of this partnership was to build an integrated "global-regional" logistics network. The proposed acquisition of 51% equity in Asiatic represents a strategic upgrade based on the successful outcomes of previous cooperation. This move aims to deepen the mechanism of shared benefits through equity binding, promoting a leapfrog development from business collaboration to strategic win-win outcomes.
Asiatic, as a benchmark company in the logistics sector of East Asia, has been deeply involved in the air freight markets of Japan and Southeast Asia since its establishment in 2007. Asia has leveraged its core services, such as "Japan Dedicated Line," "General Cargo Charter Flights," and "Special Cargo Transportation," along with the support of its subsidiary, JP International Logistics Limited (which focuses on Japanese e-commerce business), to become one of the most competitive logistics service providers in East Asia. Its main businesses, including "Hong Kong to Japan Charter Flights for E-commerce" and "Air Freight Capacity in Europe/Western Asia/Southeast Asia," complement the cross-continental air freight advantages of New Century in the United States, Europe, and the Middle East.
Core of acquisition: strengthen the Asian hub and improve the global network loop
Pursuant to the LOI, the specifics of the proposed 51% equity transaction, including the purchase price and payment terms, will be finalized through a subsequent formal acquisition agreement. This agreement will take into account various factors, such as Asiatic's financial performance, the prevailing market environment and relevant industry benchmarks.
The strategic value of the acquisition to New Century is evident in the following three key areas:
<ol>
<li>Deep cultivation in the Asian market: Asiatic's extensive local network, customs clearance experience, and e-commerce freight advantages in Japan and Southeast Asia will significantly bolster New Century's "last mile" service offerings in Asia. This is particularly crucial given the rapid growth of cross-border e-commerce, enabling New Century to solidify its position as a leading logistics hub in East Asia. &nbsp;</li>
<li>Global Link Network Expansion: By integrating Asiatic's operations with New Century's existing routes in the United States, Europe, and the Middle East, the acquisition will create a seamless "Asia-Europe-Middle East" logistics corridor. This will allow New Century to offer customers an integrated "door-to-door" cross-border transportation solution, enhancing its global logistics capabilities.</li>
<li>Resource collaboration and efficiency: The two parties will collaborate further by sharing warehousing facilities, transportation vehicles, and supply chain management systems. This synergy will optimize transportation times and costs while improving market penetration through customer referral mechanisms.</li>
</ol>
Future plan: with Japan as the core, expand the new map of Asian business
Upon the successful completion of the acquisition, New Century will designate Japan as one of its key strategic hubs in Asia, leveraging it to expand both regional and transcontinental business operations. The following initiatives outline New Century's strategic roadmap:
<ul>
<li>Strengthen the function of Japan hub: Utilizing Asiatic's "special line charter," "e-commerce" services, and the expertise of its subsidiary, JP International, Japan will be developed into a "transshipment center" for New Century's Asia region. This hub will connect Southeast Asia, Europe, America, and the Middle East markets, creating a multi-directional logistics channel that links "Japan-Southeast Asia-global; &nbsp;</li>
<li>Develop customized e-commerce logistics products: In response to the explosive growth of the Japanese cross-border e-commerce market, New Century will collaborate with Asiatic to launch a "Japan-global" e-commerce special line service. This service will cover the entire process of forward transportation, customs clearance, warehousing, and terminal distribution, offering e-commerce customers an expedited "72-hour customs clearance + 48-hour door-to-door" express logistics experience. &nbsp;</li>
<li>Deepening local resource integration: Leveraging the Asiatic team's in-depth understanding of the Japanese market, New Century plans to establish strategic partnerships with leading e-commerce platforms and manufacturing enterprises in Japan. This initiative aims to expand the customer base and enhance market penetration. &nbsp;</li>
<li>Driving digital and intelligent upgrades: New Century will integrate its self-developed "Global Supply Chain Visualization System" with Asiatic's existing management platform. This integration will enable real-time synchronization of Japanese warehousing, transportation, and customs clearance data. The enhanced system will improve the accuracy of cargo tracking and the efficiency of abnormal response, providing customers with "one-click query and whole-process control" digital services.</li>
</ul>
Integrity as the foundation, future outlook
The chairman of the New Century board stated: " Asiatic is a 'hidden champion' in the East Asian logistics markets, with deep roots in Japan and Southeast Asia. This acquisition is a perfect fit with our global network, extending our business reach and upgrading our strategic ecosystem. We will use Asia as our bridgehead to drive global logistics services toward greater efficiency and closer alignment with customer needs. Our commitment to integrity and future outlook will guide us as we build a stronger, more integrated global logistics platform."
Ms. Chiu Nga Ting, shareholder of Asiatic, pointed out: " As a NASDAQ-listed company, New Century's international resource integration capabilities and capital strength are key drivers for Asiatic's advancement into cross-continental logistics. We believe that through equity cooperation, both parties will achieve a synergistic effect where '1+1&gt;2', creating greater value for our customers. This partnership is not just about growth; it's about building a future where logistics is seamless, efficient, and customer-centric."

NCEW

New Century Logistics Enters Into LOI With Chiu Nga Ting, Sole Shareholder Of Asiatic Logistics, To Acquire 51% Of Issued And Outstanding Shares Of Asiatic

<ul>
<li>Further details will be provided in an official letter from FDA within 30 days and the company plans to address their questions, once received.</li>
<li>IND Application Submitted to Expand RESTORE-FA Trial to U.S. Sites; Notice Received from&nbsp;FDA&nbsp;Placing&nbsp;Clinical Hold&nbsp;on IND Application to Open U.S. Sites</li>
</ul>

Biotech

Health Care

General

DSGN

Design Therapeutics Submitted An Investigational New Drug Application For DT-216P2 With The FDA, The Company Received A Clinical Hold Notice On The IND Application From FDA Noting Nonclinical Deficiencies

Comments

Raytech Holding

Notizie

Ultime notizie per Raytech Holding (NASDAQ:RAY) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO